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Abstract
High-throughput sequencing (HTS) has successfully identified novel resistance genes in enterococci and determined clonal
relatedness in outbreak analysis. We report the use of HTS to investigate two concurrent outbreaks of glycopeptide-resistant
Enterococcus faecium (GRE) with an uncharacterised resistance mechanism to quinupristin-dalfopristin (QD). Seven QD-
resistant and five QD-susceptible GRE isolates from a two-centre outbreak were studied. HTS was performed to identify genes
or predicted proteins that were associated with the QD-resistant phenotype. MLST and SNP typing on HTS data was used to
determine clonal relatedness. Comparative genomic analysis confirmed this GRE outbreak involved two distinct clones (ST80
and ST192). HTS confirmed the absence of known QD resistance genes, suggesting a novel mechanism was conferring resis-
tance. Genomic analysis identified two significant genetic determinants with explanatory power for the high level of QD
resistance in the ST80QD-resistant clone: an additional 56aa leader sequence at the N-terminus of the lsaE gene and a transposon
containing seven genes encoding proteins with possible drug or drug-target modification activities. However, HTS was unable to
conclusively determine the QD resistance mechanism and did not reveal any genetic basis for QD resistance in the ST192 clone.
This study highlights the usefulness of HTS in deciphering the degree of relatedness in two concurrent GRE outbreaks. Although
HTS was able to reveal some genetic candidates for uncharacterised QD resistance, this study demonstrates the limitations of
HTS as a tool for identifying putative determinants of resistance to QD.
Keywords Quinupristin-dalfopristin . Enterococcus faecium . Enterococcal resistance . High-throughput sequencing . Outbreak
Introduction
Enterococci are Gram-positive, facultatively anaerobic cocci
that naturally colonise the human gastrointestinal tract and
commonly cause nosocomial infections [1]. In February
2017, the World Health Organization named E. faecium in a
priority list of pathogens to guide their strategy for tackling
antimicrobial resistance [2].
Quinupristin-dalfopristin (QD) is a semi-synthetic 70:30
mixture of streptogramins A and B licenced for treatment of
glycopeptide-resistant Enterococcus faecium (GRE) and
methicillin-resistant Staphylococcus aureus (MRSA) infection
[3]. Quinupristin and dalfopristin act synergistically to inhibit
the ribosomal peptide elongation cycle with bactericidal effect.
QD resistance in E. faecium is uncommon but several of its
genetic determinants have been well-described [4, 5]. In most
cases, high-level QD resistance (MIC ≥ 4 μg/ml) is conferred
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by enzymatic drug acetylation (encoded by the vat genes,
particularly vatD and vatE) or drug efflux (encoded by
vgaA, vgaB and vgaD) of quinupristin. The vat and vga fam-
ilies of genes are characteristically plasmid-borne and have
been described in other Gram-positive organisms, mainly
staphylococci [5]. Targeting of dalfopristin by resistance gene
products may also be associated with low-level QD resistance
(MIC < 4 μg/ml), with described mechanisms including drug
degradation (vgbA and vgbB), efflux (msrC) and methylation
of the 23S rRNA target site (ermB).
The discovery of novel genes and allele variants within the
already-described families of QD resistance genes has led to
speculation that there remain undiscovered genetic determinants
of resistance [6, 7]. High-throughput sequencing (HTS) of en-
terococci has successfully identified undescribed genes of resis-
tance, including those targeting linezolid, daptomycin and tige-
cycline [8–10]. HTS has also been useful in elucidating complex
transmission routes in nosocomial outbreaks of GRE [11].
Two concurrent single-ward outbreaks of GRE were re-
ported in Belfast in 2012. The two wards (ward A, a
Haematology Unit, and ward B, a Critical Care Unit) were
situated around 1 km apart within the same Hospital Trust.
There is frequent movement of healthcare workers and pa-
tients between the two sites and between the two units. In
response to the initial cases, GRE screening of new admis-
sions to ward A and ward B was instigated until resolution of
the outbreak.
GRE isolates from the outbreak were characterised by
displaying low- or high-level resistance to QD. Genetic testing
at the Public Health England Antimicrobial Resistance &
Healthcare-Associated Infection (ARHAI) Reference Unit in-
dicated the absence of vatD and vatE genes in the high-level
QD-resistant GRE isolates. The impression from epidemio-
logical and antibiogram analysis was that these isolates repre-
sented a Trust-wide outbreak. We hypothesised that a novel
genetic mechanism was conferring high-level QD resistance
in these isolates of GRE and sought to detect this mechanism
using HTS. We also postulated that HTS could determine
whether the two outbreaks were epidemiologically linked.
Materials and methods
Isolation
Enterococcal isolates were cultured from faeces of patients
from two wards (ward A and ward B) in Belfast hospitals in
the course of screening for carriage of GRE in an outbreak
setting. The minimum inhibitory concentration (MIC, μg/ml)
of QD was initially determined using an automated method
(VITEK-2®, bioMérieux) in the local laboratory and con-
firmed using agar dilution (BSAC method) at the Public
Health England reference laboratory. The QDMIC breakpoint
for resistance was defined as ≥ 4 μg/mL. Seven QD-resistant
isolates of E. faecium that were representative of both wards
over a 6-month period were selected for study. Five QD-
susceptible isolates of GRE, including one sporadic GRE iso-
late from a Hospital Trust outside Belfast (ward C), cultured
during the same screening exercise, were used as control
strains.
QD-susceptibility testing
All E. faecium isolates that were QD-resistant or QD-
susceptible by the agar dilution (BSAC method) at Public
Health England were re-tested for QD-susceptibility using
VITEK-2® (bioMérieux) in the local laboratory to confirm
the persistence of phenotypic resistance prior to DNA extrac-
tion for HTS.
PCR detection of genes of interest
The presence of genes conferring resistance to QD (vatA,
vatB, vatC, vatD, vatE, vatH, vgaA, vgaB, vgaD, vgbA,
vgbB, msrC and ermB) in the 12 isolates was assessed by
PCR amplification using primers and PCR conditions as pre-
viously published (Table 1) [6, 12, 13]. Genomic DNA was
extracted using the PureLink® Genomic DNA Purification
Kit (Invitrogen). The positive control organisms for PCRwere
S. aureus ES1767, S. aureus ES1768, E. faecium UW1965
and E. faeciumUW3540. Sterile water was used as a negative
control.
High-throughput sequencing
Sequencing libraries were prepared using the Nextera® DNA
Library Prep Kit (Illumina) according to the manufacturer’s
instructions. The target insert size for libraries was 500 bp.
Libraries were sequenced using the HiSeq 2000 sequencing
system (Illumina, San Diego, CA) using 90 bp paired-end
sequencing mode at the Beijing Genome Institute. Sequence
data quality was assessed using FastQC software (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc). All
sequences were reported to be high quality, with median
Phred quality scores above 30 across all bases for all samples.
De novo assembly
For each sample, paired-end de novo assembly was undertak-
en using clc_assembler software (http://www.clcbio.com/
products/clc-assembly-cell) with differing parameters.
Limiting the output to contigs of 200 or more bases, 7
different insert size ranges were specified: 120–500; 170–
500; 220–500; 270–500; 320–500; 370–500 and 420–500.
The optimal assembly for each sample was defined as the
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assembly containing the largest contig. These optimal
assemblies were selected for further analysis.
The Enterococcus faecium DO genome was used as a ref-
erence for contig ordering and for comparison to the study
Table 1 Primers and conditions for the detection of known QD resistance genes by PCR
Gene Primers Sequence GenBank accession
no.
Size of product
(bp)
PCR conditions
VatA Vat-1 TGGAGTGTGACAAGATAGGC L07778 512 Initial denaturing reaction at 94 °C for 3 min;
35 cycles at 94 °C for 1 min, 55 °C
for 1 min and 72 °C for 1 min;
final extension reaction
at 72 °C for 10 min
Vat-2 GTGACAACAGCTTCTGCAGC
VatB vatB-1 GGCCCTGATCCAAATAGCAT U19459 558 Initial denaturing reaction at 94 °C for 3 min;
35 cycles at 94 °C for 1 min, 55 °C for
1 min and 72 °C for 1 min; final extension
reaction at 72 °C for 10 min
vatB-2 GTGCTGACCAATCCCACCAT
VatC vatC-O ATGAATTCGCAAAATCAGCAAGG AF015628 579 Initial denaturing reaction at 95 °C for 3 min
and 60 °C for 2 min; 30 cycles at 72 °C
for 20 s, 95 °C for 20 s and 60 °C for 20 s;
final extension reaction at 72 °C for 1 min
vatC-P TCGTCTCGAGCTCTAGGTCC
VatD satA-1 GCTCAATAGGACCAGGTGTA L12033 271 Initial denaturing reaction at 94 °C for 3 min;
35 cycles at 94 °C for 1 min, 55 °C for
1 min and 72 °C for 1 min; final extension
reaction at 72 °C for 10 min
satA-2 TCCAGCTAACATGTATGGCG
VatE satG-1 ACTATACCTGACGCAAATGC AF139725 511 Initial denaturing reaction at 94 °C for 3 min;
30 cycles at 94 °C for 20 s, 52 °C for 40 s
and 72 °C for 50 s; final extension reaction
at 72 °C for 6 min
satG-2 GGTTCAAATCTTGGTCCG
vgaA vga-1 AGTGGTGGTGAAGTAACACG M90056 659 Initial denaturing reaction at 94 °C for 3 min;
35 cycles at 94 °C for 1 min, 55 °C for
1 min and 72 °C for 1 min; final
extension reaction at 72 °C for 10 min
vga-2 CTTGTCTCCTCCGCGAATAC
vgaB vgaB-1 TGACAATATGAGTGGTGGTG U82085 576 Initial denaturing reaction at 94 °C for 3 min;
35 cycles at 94 °C for 1 min, 52 °C for
1 min and 72 °C for 1 min; final
extension reaction at 72 °C for 10 min
vgaB-2 GCGACCATGAAATTGCTCTC
vgbA vgb-1 TACAGAGTACCCACTACCGA M36022 569 Initial denaturing reaction at 94 °C for 3 min;
35 cycles at 94 °C for 1 min, 52 °C for
1 min and 72 °C for 1 min; final
extension reaction at 72 °C for 10 min
vgb-2 TCAATTCCTGCTCCAGCAGT
vgbB vgbB-Q CAGCAGTCTAGATCAGAGTGG AF015628 728 Initial denaturing reaction at 95 °C for 3 min
and 60 °C for 2 min; 30 cycles at 72 °C for
20 s, 95 °C for 20 s and 60 °C for 20 s;
final extension reaction at 72 °C for 1 min
vgbB-R CATACGGATCCATCTTTTCC
ermB1 ermB-1 CATTTAACGACGAAACTGGC M11180 424 Initial denaturing reaction at 94 °C for 3 min;
25 cycles at 94 °C for 1 min, 52 °C for
1 min and 72 °C for 1 min; final
extension reaction at 72 °C for 10 min
ermB-2 GGAACATCTGTGGTATGGCG
vatH vatG1 GTGGGAAAAGCATACACCT GQ205627 200 Initial denaturing reaction at 94 °C for 5 min;
30 cycles at 94 °C for 30 s, 55 °C for 30 s,
and 72 °C for 30 s; final extension reaction
at 72 °C for 10 min
vatG2 TTGCAGGATTACCACCAAC
vgaD vgaD1 CAACTGGAGCGAGCTGTTA GQ205627 201 Initial denaturing reaction at 94 °C for 5 min;
30 cycles at 94 °C for 30 s, 55 °C for 30 s,
and 72 °C for 30 s; final extension reaction
at 72 °C for 10 min
vgaD2 GACAGCCGGATAATCTTTTG
msrC msrC3 AAGGAATCCTTCTCTCTCCG AJ243209 343 Initial denaturing reaction at 95 °C for 3 min;
35 cycles 93 °C for 30 s, and 55 °C for
2 min at 72 °C for 90 s; final extension
reaction at 72 °C for 10 min
msrC4 GTAAACAAAATCGTTCCCG
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strains. This strain is susceptible to QD (MIC ≤ 1 μg/mL). The
DO genome comprises a chromosome (NC_017960,
2,698,137 bp) and three plasmids (NC_017961, plasmid 1,
36,262 bp; NC_017962, plasmid 2, 66,247 bp and
NC_017963, plasmid 3, 251,926 bp). For each sample,
contigs were ordered using BLASTN comparison to the DO
genome. Contig order relative to the DO genome was used to
generate a reordered assembly for each sample. Contigs that
did not align to the DO reference were placed first in the
reordered assembly. Gaps between contigs which were ‘size-
unknown’ were indicated with a block of 100 N residues.
Other N residues in the assemblies indicated of gaps of known
length, based on read-pair insert size distributions.
Annotation
Identification of predicted CDS (coding segment) re-
gions in the assemblies used a combination of two ap-
proaches: ab initio ORF finding using Artemis (http://
www.sanger.ac.uk/science/tools/artemis) software and
transitive annotation using BLAST from known E.
faecium predicted proteins. A dataset (‘EfecDB’)
comprising all 670,389 E. faecium predicted proteins
was downloaded from NCBI. For each predicted CDS
in each assembly, the EfecDB database was searched
using BLASTP. The ‘most similar protein’ description
line was used to assign a protein product to each
predicted CDS.
MLST alleles
MLST allele sequences (atpA, ddl, gdh, purK, gyd, pstS
and adk) for E. faecium were downloaded from the
PubMLST database (https://pubmlst.org/efaecium). These
alleles were identified in assembled HTS data from the
sequenced strains using blastn and the PubMLST batch
sequence query tool. The resulting allelic profiles were
used to assign sequence types.
Genome-wide single nucleotide polymorphism
analysis
HTS data were used to generate phylogenies based on single
nucleotide polymorphism (SNP) analysis, using two different
methods. The first method (described by Kaas et al.) was im-
plemented on the Centre for Genomic Epidemiology server
(https://cge.cbs.dtu.dk/services/CSIPhylogeny) [14]. The
second method (described by Bertels et al.) was implemented
on the REALPHY server v1.12 (https://realphy.unibas.ch/fcgi/
realphy) [15].
Specific genes of interest
To identify specific genes of interest in the assemblies, protein
sequences were obtained from NCBI (see Appendix 1).
Each sequence was used to search all of the predicted pro-
tein sequences in the assemblies using BLASTP, allowing up
to 500 hits. The outputs were parsed on the basis of hsp
bitscore, a measure of similarity and extent of the similarity
region, using a very stringent bitscore threshold of > 250. All
hits were aligned with the query sequence and the resulting
multiple sequence alignments were manually inspected using
GeneDoc (http://www.nrbsc.org/old/gfx/genedoc).
Comparative genomic analysis
Two rounds of analysis were undertaken to identify genes/
predicted proteins that were associated with the QD-resistant
phenotype. The first round identified predicted proteins in the
assemblies that were present or absent from the DO reference
genome, using BLASTPwith a non-stringent 20% amino acid
identity threshold. However, this analysis did not identify pre-
dicted proteins that were absent from the DO genome and only
present in resistant strains. To address this, a second round of
analysis was carried out, with reference to a ‘pan genome’
constructed using CDS data from all of the sequenced strains.
This analysis aimed to identify homologous genes (proteins)
that were present only in the assemblies from resistant strains
and/or only present in resistant strains with the same MLST
sequence type. A BLASTN threshold of 70% nucleotide iden-
tity was applied for this analysis.
Results
PCR detection of genes of interest
No PCR products were obtained using published primer sets
for vatA, vatB, vatC, vatD, vatE, vatH, vgaA, vgaB, vgaD,
vgbA and vgbB on genomic DNA extracted from any of the
QD-resistant or QD-susceptible isolates. All of the tested iso-
lates (both QD-resistant and sensitive) were PCR positive
using msrC and ermB primers. For the positive controls,
PCR products were seen at the expected band sizes for
S. aureus ES1767 (vatA, vgaA, vgbA), S. aureus ES1768
(vatB, vgaB), E. faecium UW1965 (vatD) and E. faecium
UW3540 (vatE).
Multi-locus sequence typing (MLST) by HTS
MLST allele sequences (atpA, ddl, gdh, purK, gyd, pstS and
adk) were identified in assembled HTS datasets for each strain
and used to assign MLST sequence types. All seven alleles
were identified in all of the sequenced strains, and all strains
Eur J Clin Microbiol Infect Dis
had known allelic profiles/sequence types. MLST demonstrat-
ed that the two concurrent outbreaks were each dominated by
a single clone of QD-resistant E. faecium: four QD-resistant
isolates were type ST80, of which three were isolated from
ward A; three were ST192 and all isolated from ward B. One
QD-susceptible isolate of E. faecium was also type ST192,
with the other three QD-susceptible isolates having different
ST types (Table 2).
Genome-wide SNP analysis using two different software
pipelines confirmed the strains that were designated as ST80
using MLST formed a single monophyletic cluster and were
effectively indistinguishable from each other based on SNPs
(Fig. 1).
Comparative genomic analysis
Comparative genomic analysis was performed, comparing the
assembled HTS datasets from the QD-resistant isolates (ST80
and ST192 strains), QD-susceptible isolates (all ST types) and
the QD-sensitive E. faecium DO reference strain. The first
comparison was to a list of genes encoding proteins of interest
that are known to be associated with QD resistance. All of the
sequenced strains contained ermB, msrC (as expected from
the PCR data) and also lsaE homologues. However there were
no genes (using at least 20% amino acid sequence similarity as
a cutoff) belonging to the vat (vatA, vatB, vatC, vatD, vatE,
vatG) or vga (vgaA, vgaB, vgaD) families identified in the
QD-resistant or QD-susceptible isolates.
The second comparison was of all predicted protein-coding
genes identified in the sequenced strains (n = 36,664 in total)
to both the DO reference genome (n = 3114 genes) and to a
‘pan genome’ of sequences present in at least one of the se-
quenced strains, but not in the DO reference genome (n =
4131 genes). This comparison, using a less stringent cutoff
(70% similarity at the DNA level) identified two genetic foci
of interest.
First, a total of 68 predicted proteins were identified that
were present only in the resistant ST80 strains. Fifty-five of
the genes encoding these were located in eight syntenic clus-
ters, corresponding to operons encoding saccharide metabo-
lism, polysaccharide/capsule biosynthesis, or to transposons
(identified by the presence of one ormore genes annotated as a
transposase). None of the 68 predicted proteins were annotat-
ed with functions that might confer QD resistance. The com-
parative analysis did identify a putative multidrug resistance
transposon comprised of eight genes located in a single prob-
able transposon in all of the ST80 strains. However, these
genes were also present, with six additional flanking genes
(HMPREF0351_12793, HMPREF0351_12806) as a transpo-
son in the (QD susceptible) reference genome. Of note, two
upstream genes to the transposon in the DO strain encode
transcriptional regulators which were absent from the ST80
isolates: HMPREF0351_12795, a hypothetical WYL family Ta
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DNA-binding transcriptional regulator (118 aa) and
HMPREF0351_12796, a DNA-binding transcriptional regu-
lator YafY containing HTH and WYL domains (190 aa). A
further gene encoding a putative transcriptional repressor pro-
tein (HMPREF0351_12805) was present in the DO transpo-
son, but absent from the ST80 assemblies. Analysis of this
transposon, which may be de-repressed in the resistant ST80
isolate through the absence of the transcriptional regulators,
predicted that it encodes several proteins with possible drug or
drug-target modification activities. These include putative
kanamycin kinase, streptothricin acetyltransferase, streptomy-
cin aminoglycoside 6-adenyltransferase, SAM-dependent
methyltransferase and rRNA (adenine-N(6)-)-methyltransfer-
ase enzymes. In addition, the transposon includes an uniden-
tified DNA polymerase domain-containing protein and a
small (81aa), unnamed hypothetical protein of unknown func-
tion belonging to the DUF1413 superfamily (http://pfam.
xfam.org/family/PF07205).
The second observation of interest was an additional 56aa
leader sequence at the N-terminus of the lsaE gene in the ST80
QD-resistant isolates that was not seen in the non-ST80 QD-
resistant isolates, the QD-susceptible isolates or the DO refer-
ence strain. This gene encodes a homologue for the ATP-
binding cassette (ABC) protein that is responsible for QD
resistance in E. faecalis [16]. A point mutation in this gene
(C1349T) has reportedly conferred QD resistance (MIC 4) to
E. faecium [17]. However, this 56aa leader sequence has been
found in another reference strain, E faecium TX1330, which
we confirmed is QD-susceptible.
There were no unique genetic determinants found in the
ST192 QD-resistant isolates that were absent from the ST80
QD-resistant isolates, the QD-susceptible isolates and/or the
DO reference strain.
Discussion
The potential of high-throughput sequencing is an exciting
development in diagnostic bacteriology [18]. To date, the
leading application of HTS has been determining clonal relat-
edness of bacterial isolates in outbreak analysis. However, as
antimicrobial resistance is a growing priority in clinical re-
search, HTS has been used to identify novel genes of interest.
In enterococcal studies, HTS has already characterised previ-
ously unknown genes that confer resistance to linezolid, dap-
tomycin and tigecycline [8–10]. This study sought to identify
the novel genetic determinant for QD resistance in our isolates
of GRE using HTS and determine the relatedness of two con-
current outbreaks. There are three principal findings from this
study, with attendant implications.
First, PCR and HTS analysis confirmed that the QD-
resistant E. faecium in this outbreak did not encode any known
genes that confer high-level resistance toQD. This concurs with
the recognition elsewhere that there remain uncharacterised QD
(S): QD-susceptible; (R): QD-resistant
Fig. 1 Cladogram depicting the
clonal relatedness of Enterococcal
isolates studied in this outbreak. S
QD-susceptible, R QD-resistant
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resistance mechanisms among enterococci [6, 7]. Gene targets
of interest that were not found using the search strategy
employed may have been genuinely absent from the genomes,
present in the genome but missing from the assemblies, or not
detected due to divergence at the primary sequence level. We
consider the latter to be unlikely as two Lsa-family ABC trans-
porter variants that were distinct from—but clearly homologous
to—the LsaE query sequence (amino acid sequences were 43%
identical and 94% conserved physicochemical properties) were
identified using this approach.
On account of the limitations of HTS and assembly strate-
gy, none of the study strains was sequenced to closed genomes
so we cannot exclude missing contigs which may harbour
resistance determinants.
Currently, QD is not commonly used to treat serious GRE
infections, as it has been superseded by agents that are easier
to administer and are better tolerated. However, as GRE in-
fections increase in number and acquire further drug resis-
tance, we might expect to see greater dependence on QD in
future clinical practice. Rapid resistance screening tests based
on currently characterised resistance genes would have failed
to detect QD resistance in some of these isolates implicated in
this study. This has potential to delay the commencement of
appropriate treatment, which could have adverse conse-
quences for patient outcomes in the context of a QD-
resistant GRE outbreak.
Second, HTS was useful in demonstrating the multi-clonal
nature of this GRE outbreak. The benefit of typing outbreak
strains for identifying infection source and transmission routes
is well recognised [11, 18]. MLST typing of the HTS data
revealed that two clones dominated this outbreak which linked
strongly to the ward from which they were isolated: three of
four ST80 isolates came from ward A and all four ST192
isolates came from ward B. This alerts infection control prac-
titioners against presuming the association of outbreaks that
appear linked in space and time, even if they share atypical
features such as unusual antibiograms.
A number of ST80 strains (n = 17) from hospitalised pa-
tients and/or outbreaks in the UK, Europe, Asia and Africa are
listed in the PubMLST E. faecium isolates database. The ear-
liest ST80 strain in the database was isolated in Israel in 1997.
ST80 is a single-locus variant of the globally disseminated
multidrug-resistant ST117 clone and represents a further inter-
national hospital-adapted GRE clone [19]. To our knowledge,
this is the first study to genomically characterise ST80 strains
and to confirm they are circulating in Ireland.
Finally, HTS was of limited usefulness in determining the
genetic determinant for QD resistance in this outbreak. After
comparative genomic analysis revealed this GRE outbreak
was dominated by two distinct clones (ST80 and ST192), it
demonstrated that there was no single, consistent genetic deter-
minant for the QD resistance in these isolates. For the ST192
QD-resistant isolates, HTS analysis did not reveal any
significant genetic differences from the QD-susceptible control
isolates in the study. However, there were two genetic differ-
ences of interest present in the ST80QD-resistant isolates which
were absent in the non-ST80 QD-resistant isolates, the QD-
susceptible controls and DO reference strain. These were (i) an
additional 56aa leader sequence at the N-terminus of the lsaE
gene and (ii) a potentially de-repressed transposon encoding five
proteins with possible uncharacterised drug-target modification
activities plus a hypothetical protein of unknown function.
Leader sequences have been implicated in inducible
streptogramin resistance elsewhere. For example, streptogramins
bind to the leader sequence ErmBL which stalls ribosome trans-
lation and triggers expression of ermB which inactivates the an-
tibiotic through methylation [20, 21]. We found the same leader
sequence of the lsaE gene in another E. faecium reference strain
(TX1330) which is QD susceptible; however, this is not a truly
comparable strain since it does not encode the low-level QD
resistance gene ermB and is susceptible to glycopeptides [22].
Therefore, the 56aa leader sequence in the lsaE gene may possi-
bly combine with the gene products of ermB or the depressed
transposon of interest to generate the high-level QD resistance
seen in the ST80 isolates.
From this study, we conclude that HTS was useful in demon-
strating that two concurrent GRE outbreaks, both characterised
by unusual QD resistance, were not directly related. It was also
helpful in identifying significant genetic differences that offer
plausible explanations for QD resistance in some, but not all, of
theGRE in this outbreak.We conclude that there aremechanisms
of QD resistance in enterococci that are not readily detectable
through genomic analysis. This corresponds with the experience
of others who have not been successful in using HTS to identify
enterococcal mechanisms of linezolid resistance [23]. One pos-
sible explanation for this is the presence of resistance determi-
nants that originate beyond the genome. The study of proteomics,
for instance, has identified post-translational modifications that
can confer antimicrobial resistance that may not be predicted by
HTS [24]. As enterococcal resistance increases, QD may form
part of our GRE treatment strategy in the future and further work
is warranted to characterise QD resistance mechanisms at the
post-genomic level.
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Appendix 1: QD resistance Genes of Interest
To identify specific QD resistance genes of interest in the
assemblies, the following protein sequences were obtained
from NCBI:
gi|398085|gb|AAA26683.1|VatA VatA acetyltransferase
[Staphylococcus aureus]
gi|1181627|gb|AAA86871.1|VatB VatB [Staphylococcus
aureus]
gi|3660657|gb|AAC61671.1|VatC VatC streptogramin A
acetyl transferase [Staphylococcus cohnii]
gi|433715|gb|AAA24783.1|VatD VatD SatA streptogramin
A acetyltransferase [Enterococcus faecium]
gi|5532424|gb|AAD44719.1|VatE VatE SatG protein
[Enterococcus faecium]
gi|261607834|gb|ACX92987.1|VatG VatG streptogramin
A acetyltransferase [Enterococcus faecium]
gi|153125|gb|AAA26684.1|VgaA VgaA ATP-binding
protein [Staphylococcus aureus]
gi|2769708|gb|AAB95639.1|VgaB VgaB pristinamycin
resistance protein VgaB [Staphylococcus aureus]
gi|262340499|gb|ACX92986.2|VgaD VgaD ABC trans-
porter [Enterococcus faecium]
gi|150754|gb|AAA98259.1|VgbAVgbAvirginiamycin B
hydrolase [Plasmid pIP630]
gi|3660656|gb|AAC61670.1|VgbB VgbB streptogramin
B lactonase [Staphylococcus cohnii]
gi|21492653|gb|AAA27452.2|ErmB ErmB [Enterococcus
faecalis]
gi|12659044|gb|AAK01167.1|MsrCMsrC [Enterococcus
faecium]
gi|565363052|gb|AHC08069.1|LsaE LsaE [Enterococcus
faecium]
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Arias CA, Murray BE (2012) The rise of the Enterococcus: beyond
vancomycin resistance. Nat Rev. Microbiol 10:266–278
2. World Health Organisation (2017) Global priority list of antibiotic-
resistant bacteria to guide research, discovery, and development of
new antibiotics. http://www.who.int/medicines/publications/WHO-
PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1.
3. UK Drug Information Pharmacists Group (2000) New medicines
on the market: quinupristin-dalfopristin. http://www.ukmi.nhs.uk/
NewMaterial/html/docs/quinupri.pdf.
4. Hollenbeck BL, Rice LB (2012) Intrinsic and acquired resistance
mechanisms in Enterococcus. Virulence 3:421–433
5. Hershberger E, Donabedian S, Konstantinou K, Zervos MJ (2004)
Quinupristin-dalfopristin resistance in Gram-positive bacteria: mech-
anism of resistance and epidemiology. Clin Infect Dis 38:92–98
6. Jung YH, Shin ES, KimO, Yoo JS, Lee KM, Yoo JI, Chung GT, Lee
YS (2010) Characterization of two newly identified genes, vgaD and
vatH, conferring resistance to streptogramin A in Enterococcus
faecium. Antimicrob Agents Chemother 54:4744–4749
7. Soltani M, Beighton D, Philpott-Howard J, Woodford N (2001)
Identification of vat(E-3), a novel gene encoding resistance to
quinupristin-dalfopristin in a strain of Enterococcus faecium from
a hospital patient in the United Kingdom. Antimicrob Agents
Chemother 45:645–646
8. do Prado GV, Marchi AP, Moreno LZ, Rizek C, Amigo U, Moreno
AM, Rossi F, Guimaraes T, Levin AS, Costa SF (2016) Virulence
and resistance pattern of a novel sequence type of linezolid-resistant
Enterococcus faecium identified by whole-genome sequencing. J
Glob Antimicrob Resist 6:27–31
9. Tran TT, Panesso D, Gao H, Roh JH, Munita JM, Reyes J, Diaz L,
Lobos EA, Shamoo Y, Mishra NN, Bayer AS, Murray BE,
Weinstock GM, Arias CA (2013) Whole-genome analysis of a
daptomycin-susceptible enterococcus faecium strain and its
daptomycin-resistant variant arising during therapy. Antimicrob
Agents Chemother 57:261–268
10. Cattoir V, Isnard C, Cosquer T, Odhiambo A, Bucquet F, Guérin F,
Giard JC (2015) Genomic analysis of reduced susceptibility to tige-
cycline in Enterococcus faecium. Antimicrob Agents Chemother
59:239–244
11. Raven KE, Gouliouris T, Brodrick H, Coll F, Brown NM, Reynolds
R, Reuter S, Török ME, Parkhill J, Peacock SJ (2017) Complex
routes of nosocomial vancomycin-resistant Enterococcus faecium
transmission revealed by genome sequencing. Clin Infect Dis 64(7):
886–893
12. Soltani M, Beighton D, Philpott-Howard J, Woodford N (2000)
Mechanisms of resistance to quinupristin-dalfopristin among iso-
lates of Enterococcus faecium from animals, raw meat, and hospital
patients in Western Europe. Antimicrob Agents Chemother 44(2):
433–436
13. Werner G, Hildebrandt B, Witte W (2001) The newly described
msrC gene is not equally distributed among all isolates of
Enterococcus faecium. Antimicrob Agents Chemother 45(12):
3672–3673
14. Kaas RS, Leekitcharoenphon P, Aarestrup FM, Lund O (2014)
Solving the problem of comparing whole bacterial genomes across
different sequencing platforms. PLoS One 9(8):e104984
15. Bertels F, Silander OK, Pachkov M, Rainey PB, van Nimwegen E
(2014) Automated reconstruction of whole-genome phylogenies
from short-sequence reads. Mol Biol Evol 31(5):1077–1088
16. Singh KV, Weinstock GM, Murray BE (2002) An Enterococcus
faecalis ABC homologue (Lsa) is required for the resistance of this
species to clindamycin and quinupristin-dalfopristin. Antimicrob
Agents Chemother 46:1845–1850
Eur J Clin Microbiol Infect Dis
17. Isnard C, Malbruny B, Leclercq R, Cattoir V (2013) Genetic
basis for in vitro and in vivo resistance to lincosamides,
streptogramins A, and pleuromutilins (LSAP phenotype) in
Enterococcus faecium. Antimicrob Agents Chemother 57:
4463–4469
18. Didelot X, Bowden R, Wilson DJ, Peto TE, Crook DW (2012)
Transforming clinical microbiology with bacterial genome se-
quencing. Nat Rev. Genet 13:601–612
19. Tedim AP, Lanza VF, Manrique M, Pareja E, Ruiz-Garbajosa P,
Cantón R, Baquero F, Coque TM, Tobes R (2017) Complete ge-
nome sequences of isolates of Enterococcus faecium sequence type
117, a globally disseminated multidrug-resistant clone. Genome
Announc 5(13):e01553–e01516
20. Leclercq R, Courvalin P (1991) Bacterial resistance to macrolide,
lincosamide, and streptogramin antibiotics by target modification.
Antimicrob Agents Chemother 35:1267–1272
21. Arenz S, Ramu H, Gupta P, Berninghausen O, Beckmann R,
Vázquez-Laslop N, Mankin AS, Wilson DN (2014) Molecular
basis for erythromycin-dependent ribosome stalling during transla-
tion of the ErmBL leader peptide. Nat Commun 5:3501
22. Qin X, Galloway-Peña JR, Sillanpaa J, Roh JH, Nallapareddy SR,
Chowdhury S, Bourgogne A, Choudhury T, Muzny DM, Buhay
CJ, Ding Y, Dugan-Rocha S, Liu W, Kovar C, Sodergren E,
Highlander S, Petrosino JF, Worley KC, Gibbs RA, Weinstock
GM, Murray BE (2012) Complete genome sequence of
Enterococcus faecium strain TX16 and comparative genomic anal-
ysis of Enterococcus faecium genomes. BMC Microbiol 12:135
23. Chacko K, Pak T, Sebra R, Kasarskis A, Hamula C, Van Bakel H
(2016) Longitudinal whole-genome analysis identifies variants as-
sociated with vancomycin and linezolid resistance changes in
Enterococcus faecium in response to treatment. Abstr Open
Forum Infect Dis, abstr 2001
24. Wang X, He X, Jiang Z, Wang J, Chen X, Liu D, Wang F, Guo Y,
Zhao J, Liu F, Huang L, Yuan J (2010) Proteomic analysis of the
Enterococcus faecalis V583 strain and clinical isolate V309 under
vancomycin treatment. J Proteome Res 9:1772085
Eur J Clin Microbiol Infect Dis
